Zeina Nahleh, MD
Medical Oncology · El Paso, TXNPI 1790742476
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,711 of the $2,722 with a category attached, or 62.8%. 27 manufacturers reported payments, led by Athenex Pharmaceutical Division, LLC at 37.5% of the total. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 83 payments — averaging $32.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Athenex Pharmaceutical Division, LLC$1K
- Novartis$252
- Johnson & Johnson$248
- Daiichi Sankyo Inc.$137
- Tersera Therapeutics LLC$126
- AstraZeneca$121
- plus $816 from 21 others
Across 4 payments — averaging $5184.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$20K
- Merck$542
What the payments were for
- Speaking & faculty fees$1,00037%
- Food & beverage$1,71163%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Athenex Pharmaceutical Division, LLC | 3 | $1,022 |
| Novartis | 15 | $252 |
| Johnson & Johnson | 6 | $248 |
| Daiichi Sankyo Inc. | 6 | $137 |
| Tersera Therapeutics LLC | 5 | $126 |
| AstraZeneca | 5 | $121 |
| Merck | 7 | $117 |
| Pfizer | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Eisai Inc. | 4 | $63 |
| GSK | 3 | $57 |
| Servier Pharmaceuticals LLC | 2 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Medtronic | 1 | $44 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Genentech USA, Inc. | 1 | $32 |
| Genentech, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
| Beigene USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oral Paclitaxel$1,000
- Encequidar$1,000
- RYBREVANT$150
- CARVYKTI$150
How this compares
$2,722 in reported general payments places this provider in the 40th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 39 | $746 |
| Letrozole | 11 | $140 |
| Alendronate Sodium | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in El Paso
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.